162 related articles for article (PubMed ID: 28638271)
1. ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.
Botti G; Malzone MG; La Mantia E; Montanari M; Vanacore D; Rossetti S; Quagliariello V; Cavaliere C; Di Franco R; Castaldo L; Ametrano G; Cappuccio F; Romano FJ; Piscitelli R; Pepe MF; D'Aniello C; Facchini G
Int J Med Sci; 2017; 14(6):554-559. PubMed ID: 28638271
[TBL] [Abstract][Full Text] [Related]
2. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens.
Moatamed NA; Rao JY; Alexanian S; Cobarrubias M; Levin M; Lu D; Apple SK
Cancer Cytopathol; 2013 Jun; 121(6):320-8. PubMed ID: 23364848
[TBL] [Abstract][Full Text] [Related]
3. Expression of ProEx C in primary and metastatic urothelial carcinoma.
Liu L; Cohen C; Siddiqui MT
Diagn Cytopathol; 2015 Mar; 43(3):181-7. PubMed ID: 24975746
[TBL] [Abstract][Full Text] [Related]
4. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of ProEx C and ImmunoCyt/uCyt assays in atypical urine cytology.
Vergara-Lluri ME; Hu E; Rao JY; Levin M; Apple SK; Moatamed NA
Arch Pathol Lab Med; 2014 Sep; 138(9):1215-22. PubMed ID: 25171704
[TBL] [Abstract][Full Text] [Related]
6. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology.
Shroyer KR; Homer P; Heinz D; Singh M
Cancer; 2006 Oct; 108(5):324-30. PubMed ID: 16937378
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical patterns of ProEx C in vulvar squamous lesions: detection of overexpression of MCM2 and TOP2A.
Chen H; Gonzalez JL; Brennick JB; Liu M; Yan S
Am J Surg Pathol; 2010 Sep; 34(9):1250-7. PubMed ID: 20697251
[TBL] [Abstract][Full Text] [Related]
8. Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx™ C assay: An immunoassay which detects aberrant S-phase induction in cervical tissue.
Dixon EP; King LM; Nelson R; Simkins SG; Knapp SL; Brough GH; Lenz KL; Henderson DT; Whitehead CM; Hessling J; Brown CA; Malinowski DP
J Immunol Methods; 2017 Mar; 442():35-41. PubMed ID: 28093271
[TBL] [Abstract][Full Text] [Related]
9. A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
Aximu D; Azad A; Ni R; Colgan T; Nanji S
Int J Gynecol Pathol; 2009 Mar; 28(2):114-9. PubMed ID: 19188825
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.
Brisuda A; Háček J; Čechová M; Škapa P; Babjuk M
Cytopathology; 2019 Sep; 30(5):510-518. PubMed ID: 30943322
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions.
Shi J; Liu H; Wilkerson M; Huang Y; Meschter S; Dupree W; Schuerch C; Lin F
Hum Pathol; 2007 Sep; 38(9):1335-44. PubMed ID: 17512033
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Yan S; Coffing BN; Li Z; Xie H; Brennick JB; Beg HA; Froehlich HM; Wells WA
Anticancer Res; 2016 Jun; 36(6):2871-80. PubMed ID: 27272799
[TBL] [Abstract][Full Text] [Related]
13. Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquid-based cervical squamous cell cytology.
Beccati MD; Buriani C; Pedriali M; Rossi S; Nenci I
Cancer; 2008 Jun; 114(3):196-203. PubMed ID: 18442059
[TBL] [Abstract][Full Text] [Related]
14. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
[TBL] [Abstract][Full Text] [Related]
15. Cytohistologic correlation of recurrent urothelial carcinoma detected in urinary diversion specimens.
Xing J; Roy S; Monaco SE; Pantanowitz L
Cancer Cytopathol; 2017 Feb; 125(2):120-127. PubMed ID: 27741389
[TBL] [Abstract][Full Text] [Related]
16. Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.
Szarvas T; Nyirády P; Ogawa O; Furuya H; Rosser CJ; Kobayashi T
Methods Mol Biol; 2018; 1655():251-273. PubMed ID: 28889391
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of ProEx C immunocytochemistry and UroVysion fluorescent in-situ hybridization assays on urine cytology specimens.
Chang S; Smith E; Levin M; Rao JY; Moatamed NA
Cytojournal; 2015; 12():2. PubMed ID: 25685171
[TBL] [Abstract][Full Text] [Related]
18. The application of the Johns Hopkins Hospital Template on urine cytology.
Wu HH; Redelman M; Chen S; Grignon DJ; Cramer HM
Diagn Cytopathol; 2015 Aug; 43(8):593-7. PubMed ID: 25721938
[TBL] [Abstract][Full Text] [Related]
19. Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens.
Oberg TN; Kipp BR; Vrana JA; Bartholet MK; Fales CJ; Garcia R; McDonald AN; Rosas BL; Henry MR; Clayton AC
Diagn Cytopathol; 2010 Aug; 38(8):564-72. PubMed ID: 19937941
[TBL] [Abstract][Full Text] [Related]
20. MCM2/TOP2A (ProExC) immunohistochemistry as a predictive marker in head and neck mucosal biopsies.
Jenson EG; Baker M; Paydarfar JA; Gosselin BJ; Li Z; Black CC
Pathol Res Pract; 2014 Jun; 210(6):346-50. PubMed ID: 24630889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
